{"id":50806,"date":"2022-11-14T14:02:22","date_gmt":"2022-11-14T13:02:22","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/foxo-technologies-announces-agreement-with-haven-life\/"},"modified":"2022-11-14T14:02:22","modified_gmt":"2022-11-14T13:02:22","slug":"foxo-technologies-announces-agreement-with-haven-life","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/foxo-technologies-announces-agreement-with-haven-life\/","title":{"rendered":"FOXO Technologies Announces Agreement With Haven Life"},"content":{"rendered":"<div>\n<ul class=\"bwlistdisc\">\n<li>\n<i>FOXO LIFE signs insurance carrier to managing general agency agreement<\/i>\n<\/li>\n<li>\n<i>FOXO LIFE to begin distributing Haven Life insurance products through independent agent distribution channels<\/i>\n<\/li>\n<\/ul>\n<p>MINNEAPOLIS&#8211;(BUSINESS WIRE)&#8211;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ffoxotechnologies.com%2F&amp;esheet=52968068&amp;newsitemid=20221114005372&amp;lan=en-US&amp;anchor=FOXO+Technologies+Inc.&amp;index=1&amp;md5=8176e965b87fdd180a260a0f88cd4466\" rel=\"nofollow noopener\" shape=\"rect\">FOXO Technologies Inc.<\/a> (NYSEAM: FOXO), a technology platform company whose products and services seek to address long-standing, core problems within the life insurance industry through epigenetic longevity science, today announced that its insurance distribution subsidiary, <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ffoxolife.com%2F&amp;esheet=52968068&amp;newsitemid=20221114005372&amp;lan=en-US&amp;anchor=FOXO+LIFE&amp;index=2&amp;md5=d899807ea9964412f657083585d03899\" rel=\"nofollow noopener\" shape=\"rect\">FOXO LIFE<\/a>, signed a managing general agency agreement with Haven Life, the insurance technology arm and wholly-owned subsidiary of MassMutual, a carrier with over 170 years of strength and stability.\n<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20221114005372\/en\/1635310\/4\/FOXO-Black.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20221114005372\/en\/1635310\/21\/FOXO-Black.jpg\"><\/a><\/p>\n<p>\nFOXO LIFE and Haven Life are announcing this strategic agreement in advance of the NAILBA Annual Meeting, November 14-16, which is the largest gathering of independent life brokerage agencies, insurance carriers and independent distribution product and service providers.\n<\/p>\n<p>\nHaven Life has been an innovator within the life insurance industry for nearly a decade, introducing an end-to-end, fully digital purchasing experience for term life insurance in 2015 and expanding to other products.\n<\/p>\n<p>\n\u201cThis agreement will allow FOXO LIFE to rapidly expand its footprint among independent agent distribution channels,\u201d said <b>Jim Grauel, Jr. Chief Distribution Officer of FOXO LIFE. <\/b>\u201cWe have distribution partners excited to begin contracting and selling the innovative products offered through Haven Life.\u201d\n<\/p>\n<p>\n\u201cThe relationship between FOXO LIFE and Haven Life is a perfect fit as we grow within independent agent distribution channels,\u201d said <b>Wade Seward, Head of Partnership Distribution at Haven Life<\/b>. \u201cFOXO LIFE\u2019s emphasis on improving the consumer aging experience and enhancing healthy longevity is everything we were looking for in a partner.\u201d\n<\/p>\n<p>\n<b>About FOXO Technologies Inc. (\u201cFOXO\u201d)<\/b>\n<\/p>\n<p>\nFOXO is a technology platform company focused on commercializing longevity science into products and services that serve the life insurance industry. FOXO&#8217;s epigenetic technology applies AI to DNA methylation to identify molecular biomarkers of human health and aging. FOXO seeks to modernize the life insurance industry by simplifying the consumer underwriting journey with saliva-based biomarkers and enhancing life insurance\u2019s consumer value proposition with the FOXO Longevity Report. For more information about FOXO, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.foxotechnologies.com&amp;esheet=52968068&amp;newsitemid=20221114005372&amp;lan=en-US&amp;anchor=www.foxotechnologies.com&amp;index=3&amp;md5=f7e727a5109b921659a5cf8552fe907e\" rel=\"nofollow noopener\" shape=\"rect\">www.foxotechnologies.com<\/a>. For more information about FOXO LIFE, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.foxolife.com&amp;esheet=52968068&amp;newsitemid=20221114005372&amp;lan=en-US&amp;anchor=www.foxolife.com&amp;index=4&amp;md5=a398b119119a9d640f1e5bd28332e871\" rel=\"nofollow noopener\" shape=\"rect\">www.foxolife.com<\/a>. For investor information and updates, visit <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ffoxotechnologies.com%2Finvestors%2F&amp;esheet=52968068&amp;newsitemid=20221114005372&amp;lan=en-US&amp;anchor=https%3A%2F%2Ffoxotechnologies.com%2Finvestors%2F&amp;index=5&amp;md5=da99bff65274c4d4781dc94cfaf7bad2\" rel=\"nofollow noopener\" shape=\"rect\">https:\/\/foxotechnologies.com\/investors\/<\/a>.\n<\/p>\n<p>\n<b>About Haven Life<\/b>\n<\/p>\n<p>\nHaven Life Insurance Agency, LLC (Haven Life) is re-thinking how people financially protect the ones they love. Haven Life is committed to delivering exceptional products, delightful purchasing experiences, and meaningful moments of service to the modern life insurance customer.\n<\/p>\n<p>\n<b>No Offer or Solicitation<\/b>\n<\/p>\n<p>\nThis press release shall not constitute a solicitation of a proxy, consent or authorization with respect to any securities or in respect of the proposed transaction. This communication shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in any states or jurisdictions in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended or an exemption therefrom.\n<\/p>\n<p>\n<b>Forward-Looking Statements<\/b>\n<\/p>\n<p>\nThis press release contains certain forward-looking statements for purposes of the \u201csafe harbor\u201d provisions under the United States Private Securities Litigation Reform Act of 1995. Any statements other than statements of historical fact contained herein, including statements as to future results of operations and financial position, planned products and services, business strategy and plans, objectives of management for future operations of FOXO, market size and growth opportunities, competitive position and technological and market trends, are forward-looking statements. Such forward-looking statements include, but not limited to, expectations, hopes, beliefs, intentions, plans, prospects, financial results or strategies regarding FOXO and the future held by management teams of FOXO, the future financial condition and performance of FOXO and the products and markets and expected future performance and market opportunities of FOXO. These forward-looking statements generally are identified by the words \u201canticipate,\u201d \u201cbelieve,\u201d \u201ccould,\u201d \u201cexpect,\u201d \u201cestimate,\u201d \u201cfuture,\u201d \u201cintend,\u201d \u201cstrategy,\u201d \u201cmay,\u201d \u201cmight,\u201d \u201cstrategy,\u201d \u201copportunity,\u201d \u201cplan,\u201d project,\u201d \u201cpossible,\u201d \u201cpotential,\u201d \u201cproject,\u201d \u201cpredict,\u201d \u201cscales,\u201d \u201crepresentative of,\u201d \u201cvaluation,\u201d \u201cshould,\u201d \u201cwill,\u201d \u201cwould,\u201d \u201cwill be,\u201d \u201cwill continue,\u201d \u201cwill likely result,\u201d and similar expressions, but the absence of these words does not mean that a statement is not forward-looking. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this press release, including but not limited to: (i) the risk that changes in the competitive and highly regulated industries in which FOXO operates, variations in operating performance across competitors, changes in laws and regulations affecting FOXO\u2019s business, and changes in the combined capital structure, (ii) the ability to implement FOXO\u2019s business plans, forecasts, and other expectations, (iii) potential inability of FOXO to establish or maintain relationships required to advance its goals or to achieve its commercialization and development plans, (iv) the enforceability of FOXO\u2019s intellectual property, including its patents and the potential infringement on the intellectual property rights of others, and (v) the risk of downturns and a changing regulatory landscape in the highly competitive biotechnology industry or in the markets or industries in which FOXO\u2019s prospective customers operate, including the highly regulated insurance industry. The foregoing list of factors is not exhaustive. Readers should carefully consider the foregoing factors and the other risks and uncertainties described in the \u201cRisk Factors\u201d filed with the SEC, and risks and uncertainties indicated in the Registration Statement, including those set forth under \u201cRisk Factors\u201d therein, and other documents filed or to be filed by FOXO from time to time with the SEC. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and FOXO assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise.\n<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Contacts \/ Investor Relations<\/b><br \/>Cody Slach, Matthew Hausch<br \/>\n<br \/>Gateway Investor Relations<br \/>\n<br \/>(949) 574-3860<br \/>\n<br \/><a target=\"_blank\" href=\"&#109;&#x61;&#105;&#x6c;&#116;&#x6f;&#58;&#x46;&#79;&#x58;&#79;&#x40;g&#x61;t&#x65;w&#x61;y&#x69;r&#x2e;c&#111;&#x6d;\" rel=\"nofollow noopener\" shape=\"rect\">&#70;O&#x58;O&#x40;g&#x61;t&#x65;&#119;&#x61;&#121;&#x69;&#114;&#x2e;&#99;o&#109;<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>FOXO LIFE signs insurance carrier to managing general agency agreement FOXO LIFE to begin distributing Haven Life insurance products through independent agent distribution channels MINNEAPOLIS&#8211;(BUSINESS WIRE)&#8211;FOXO Technologies Inc. (NYSEAM: FOXO), a technology platform company whose products and services seek to address long-standing, core problems within the life insurance industry through epigenetic longevity science, today announced &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/foxo-technologies-announces-agreement-with-haven-life\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50806","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>FOXO Technologies Announces Agreement With Haven Life - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/foxo-technologies-announces-agreement-with-haven-life\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"FOXO Technologies Announces Agreement With Haven Life - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"FOXO LIFE signs insurance carrier to managing general agency agreement FOXO LIFE to begin distributing Haven Life insurance products through independent agent distribution channels MINNEAPOLIS&#8211;(BUSINESS WIRE)&#8211;FOXO Technologies Inc. (NYSEAM: FOXO), a technology platform company whose products and services seek to address long-standing, core problems within the life insurance industry through epigenetic longevity science, today announced ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/foxo-technologies-announces-agreement-with-haven-life\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-14T13:02:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221114005372\/en\/1635310\/21\/FOXO-Black.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/foxo-technologies-announces-agreement-with-haven-life\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/foxo-technologies-announces-agreement-with-haven-life\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"FOXO Technologies Announces Agreement With Haven Life\",\"datePublished\":\"2022-11-14T13:02:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/foxo-technologies-announces-agreement-with-haven-life\\\/\"},\"wordCount\":1051,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/foxo-technologies-announces-agreement-with-haven-life\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221114005372\\\/en\\\/1635310\\\/21\\\/FOXO-Black.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/foxo-technologies-announces-agreement-with-haven-life\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/foxo-technologies-announces-agreement-with-haven-life\\\/\",\"name\":\"FOXO Technologies Announces Agreement With Haven Life - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/foxo-technologies-announces-agreement-with-haven-life\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/foxo-technologies-announces-agreement-with-haven-life\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221114005372\\\/en\\\/1635310\\\/21\\\/FOXO-Black.jpg\",\"datePublished\":\"2022-11-14T13:02:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/foxo-technologies-announces-agreement-with-haven-life\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/foxo-technologies-announces-agreement-with-haven-life\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/foxo-technologies-announces-agreement-with-haven-life\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221114005372\\\/en\\\/1635310\\\/21\\\/FOXO-Black.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221114005372\\\/en\\\/1635310\\\/21\\\/FOXO-Black.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/foxo-technologies-announces-agreement-with-haven-life\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"FOXO Technologies Announces Agreement With Haven Life\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"FOXO Technologies Announces Agreement With Haven Life - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/foxo-technologies-announces-agreement-with-haven-life\/","og_locale":"en_US","og_type":"article","og_title":"FOXO Technologies Announces Agreement With Haven Life - Pharma Trend","og_description":"FOXO LIFE signs insurance carrier to managing general agency agreement FOXO LIFE to begin distributing Haven Life insurance products through independent agent distribution channels MINNEAPOLIS&#8211;(BUSINESS WIRE)&#8211;FOXO Technologies Inc. (NYSEAM: FOXO), a technology platform company whose products and services seek to address long-standing, core problems within the life insurance industry through epigenetic longevity science, today announced ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/foxo-technologies-announces-agreement-with-haven-life\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-14T13:02:22+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221114005372\/en\/1635310\/21\/FOXO-Black.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/foxo-technologies-announces-agreement-with-haven-life\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/foxo-technologies-announces-agreement-with-haven-life\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"FOXO Technologies Announces Agreement With Haven Life","datePublished":"2022-11-14T13:02:22+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/foxo-technologies-announces-agreement-with-haven-life\/"},"wordCount":1051,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/foxo-technologies-announces-agreement-with-haven-life\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221114005372\/en\/1635310\/21\/FOXO-Black.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/foxo-technologies-announces-agreement-with-haven-life\/","url":"https:\/\/pharma-trend.com\/en\/foxo-technologies-announces-agreement-with-haven-life\/","name":"FOXO Technologies Announces Agreement With Haven Life - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/foxo-technologies-announces-agreement-with-haven-life\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/foxo-technologies-announces-agreement-with-haven-life\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221114005372\/en\/1635310\/21\/FOXO-Black.jpg","datePublished":"2022-11-14T13:02:22+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/foxo-technologies-announces-agreement-with-haven-life\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/foxo-technologies-announces-agreement-with-haven-life\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/foxo-technologies-announces-agreement-with-haven-life\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221114005372\/en\/1635310\/21\/FOXO-Black.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221114005372\/en\/1635310\/21\/FOXO-Black.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/foxo-technologies-announces-agreement-with-haven-life\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"FOXO Technologies Announces Agreement With Haven Life"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50806","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50806"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50806\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50806"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50806"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50806"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}